Efficacy of bevacizumab combined with paclitaxel and carboplatin: A second line treatment of elderly patients with advanced non-small cell carcinoma (NSCLC)

4^th World Congress on Cancer Science & Therapy

October 20-22, 2014 DoubleTree by Hilton Hotel Chicago-North Shore Conference Center, USA

Abdelwahab S, Salim D, Azmy A, Margerges M and Shalabi H

Accepted Abstracts: J Cancer Sci Ther

Abstract :

Purpose: The aim of this phase II study was to assess the efficacy and safety of paclitaxel combined with carboplatin plus bevacizumab as second line treatment of elderly patients with advanced NSCLC. Patients and Methods: Twenty one previously treated elderly patients with NSCLC were enrolled into this study between March 2009 and March 2013. All patients received paclitaxel 175 mg/m2 followed by carboplatin AUC of 5, and followed by bevacizumab 15 mg/kg, all agents were given via I.V infusion on day 1 and the cycle was repeated every 21 days for maximum 6-8 cycles. Patients who attained at least stable disease continued to receive single agent bevacizumab every 21 days until disease progression or unacceptable toxicity developed. Results: The median age was 73 years old (range 66-82 years); 17 (81%) patients were men; ECOC PS was 0 in 4 (19%) patients, 1 in 9 (43%) patients and 2 in 8 (38%) patients. The objective response rate was 30.3%, while disease control rate was 63.7%, respectively, and the median progression-free survival time was 4. 2 months. Grade 3/4 neutropenia had been recorded in 4(19%) patients, grade ¾ thrombocytopenia occurred in 2(10%) patients, while grade 3/4 peripheral neuropathy occurred in 3(14%) patients and grade 3/4 fatigue had occurred in 4(19%) patients. No treatment-related deaths had been reported in this study. Conclusion: Bevacizumab when given with paclitaxel and carboplatin exhibits activity in previously treated elderly patients with advanced NSCLC and has acceptable toxicity.